• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Immunitybio Inc (NQ: IBRX )

    5.280 +0.070 (+1.34%)
    Streaming Delayed Price Updated: 4:00 PM EDT, Nov 1, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Immunitybio Inc

    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    63 Biggest Movers From Friday
    Gainers Spruce Biosciences, Inc. (NASDAQ: SPRB) jumped 102.8% to close at $5.03 on Friday after Oppenheimer initiated coverage on the stock with an Outperform rating and a $15... 
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Gainers Cumberland (NASDAQ:CPIX) stock... 
    Via Benzinga
    52 Biggest Movers From Yesterday
    Gainers Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) shares climbed 128.6% to close at $5.03 on Tuesday. The FDA approved expanded labeling for Cumberland... 
    Via Benzinga
    Exposures Product Safety
    ImmunityBio Expands Vaccine Program to Accelerate Use of “Mix-and-Match” Technologies in Developing and Manufacturing Next-Generation COVID-19 Vaccines
    From ImmunityBio, Inc.
    Via Business Wire
    Amyris, ImmunityBio Join Forces For Next-Gen COVID-19 RNA Vaccine
    Amyris Inc (NASDAQ: AMRS) has entered into a 50:50 joint venture arrangement with ImmunityBio Inc (NASDAQ: IBRX) to commercialize a next-gen COVID-19... 
    Via Benzinga
    Exposures COVID-19
    ImmunityBio to Present at the Jefferies London Healthcare Conference
    From ImmunityBio, Inc.
    Via Business Wire
    Jim Cramer Advises Buying AZEK, Considers This Stock "Great Long-Term Story"
    On CNBC’s "Mad Money Lightning Round,&q... 
    Via Benzinga
    ImmunityBio Meets Endpoint In Second Indication Cohort In Bladder Cancer Trial
    ImmunityBio Inc (NASDAQ: IBRX) has announced that Papillary disease (Cohort B) of its Phase 2/3 study of intravesical BCG plus Anktiva met its primary endpoints ... 
    Via Benzinga
    ImmunityBio Announces Primary Endpoint Met in a Second Indication in Bladder Cancer Trial with 57% Disease-Free Survival in Patients with BCG Unresponsive Papillary Disease
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Completes Enrollment in Phase 2 Study of Nant Cancer Vaccine for 3rd Line or Greater Metastatic Pancreatic Cancer Patients—90% of Patients Have Exceeded Historical Survival Rates to Date
    From ImmunityBio, Inc.
    Via Business Wire
    National Cancer Institute Selects ImmunityBio’s N-803 IL-15 Receptor Agonist to Combine with Keytruda in 700-Site Lung-MAP Clinical Trial of a Chemo-Free Therapy
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces Positive Durable Responses in BCG Unresponsive Bladder Cancer Patients with a Complete Response Rate of 72%, Median Duration of Complete Response of 19.9 Months, and 85% Remaining Cystectomy-free in Phase 2/3 Trial
    From ImmunityBio, Inc.
    Via Business Wire
    The Daily Biotech Pulse: Apellis Sinks On Data, Endo Shines On Opioid Litigation Settlement, T2 Biosystems Soars On Mutant Detection Ability of COVID Test
    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 9) Adagio Therapeutics, Inc. (... 
    Via Benzinga
    Johnson & Johnson Plans COVID-19 Booster Shot Trial In South Africa: Bloomberg
    Johnson & Johnson (NYSE: JNJ) is reportedly considering running a COVID-19 vaccine booster trial in South Africa after its jab was used in a mass trial of... 
    Via Benzinga
    Exposures COVID-19
    ImmunityBio Builds Commercial Team with the Appointment of Seasoned Marketing and Reimbursement Executives
    From ImmunityBio, Inc.
    Via Business Wire
    The Week Ahead In Biotech (Sept. 5-11): Focus On Conferences and Clinical Readouts In Another Quiet Week
    Biotech stocks extended their gains in the week ending Sept. 3, partly aided by the broader market strength. The news flow was fairly light ahead of the Labor Day holiday... 
    Via Benzinga
    ImmunityBio Announces Oral Presentation of Phase 2/3 Clinical Trial Results of Patients with BCG-Unresponsive Bladder Cancer Carcinoma at the Upcoming American Urological Association’s Annual Meeting
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Appoints Dr. Patrick Soon-Shiong to Global Chief Scientific and Medical Officer; Newly Created Role Will Lead Company’s Scientific Strategy and Global Expansion
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio’s Novel Immunotherapy NANT Cancer Vaccine Currently Being Studied in Multiple Clinical Trials Is Awarded a U.S. Patent
    From ImmunityBio, Inc.
    Via Business Wire
    Stocks That Hit 52-Week Lows On Wednesday
    Wednesday morning saw 57 companies set new 52-week lows. Noteworthy Points: Campbell Soup (NYSE:CPB) was the largest firm by market cap to set a new 52-week low.... 
    Via Benzinga
    ImmunityBio Announces Authorization to Proceed with Phase 1/2/3 Randomized Trial in South Africa of Their Dual-Antigen T-Cell Vaccine as a Universal Boost in Previously Vaccinated Participants Against COVID-19
    From ImmunityBio, Inc.
    Via Business Wire
    Cramer Weighs In On Cloudflare, MP Materials And More
    On CNBC's "Mad Money Lightning Round," Jim Cramer said he should talk more about Cloudflare Inc (NYSE: NET) on the show because it has got a great security component... 
    Via Benzinga
    ImmunityBio and NantOmics Announce Clinical Validation of a Proprietary Method to Identify Unique Targets for Immunotherapy in Individual Breast Cancer Patients
    From ImmunityBio, Inc.
    Via Business Wire
    FDA Authorizes ImmunityBio Study of Anktiva and PD-L1 t-haNK to Increase Effectiveness of Trodelvy in Triple-Negative Breast Cancer
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio Announces HIV Clinical Pipeline with Opening of a Phase 1 ‘HIV Cure Study’ in Patients Off Therapy and a Phase 2 Study in Acutely Infected Patients
    From ImmunityBio, Inc.
    Via Business Wire
    60 Biggest Movers From Yesterday
    Gainers Ra Medical Systems, Inc. (NYSE: RMED) shares surged 87.3% to close at $9.14 on Monday on abnormally-high session volume. EXFO Inc. (NASDAQ: EXFO) gained 60.3% to settle... 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Gainers Atossa Therapeutics (NASDAQ:ATOS)... 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's After-Market Session
    Gainers Adamis Pharmaceuticals (NASDAQ:ADMP 
    Via Benzinga
    ImmunityBio Expands Trials of T-Cell-Based COVID-19 Vaccine Candidate as a ‘Universal Boost’ in Vaccinated Subjects and Receives Approval to Test Intranasal Spray in South Africa
    From ImmunityBio, Inc.
    Via Business Wire
    ImmunityBio to Present at the Jefferies 2021 Virtual Healthcare Conference
    From ImmunityBio, Inc.
    Via Business Wire
    < Previous 1 2
    ...
    4 5 6 7 8 9 10 11 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.